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This study was undertaken to evaluate an enzyme immunoassay (EIA) for hepatitis C virus antibody
detection (anti-HCV), using just one antigen. Anti-HCV EIA was designed to detect anti-HCV IgG using
on the solid-phase a recombinant C22 antigen localized at the N-terminal end of the core region of HCV
genome, produced by BioMérieux.  The serum samples diluted in phosphate buffer saline were added to
wells coated with the C22, and incubated.  After washings, the wells were loaded with conjugated anti-
IgG, and read in a microtiter plate reader (492 nm). Serum samples of 145 patients were divided in two
groups: a control group of 39 patients with non-C hepatitis (10 acute hepatitis A, 10 acute hepatitis B,
9 chronic hepatitis B, and 10 autoimmune hepatitis) and a study group consisting of 106 patients with
chronic HCV hepatitis. In the study group all patients had anti-HCV detected by a commercially avail-
able EIA (Abbott®), specific for HCV structural and nonstructural polypeptides, alanine aminotrans-
ferase elevation or positive serum HCV-RNA detected by nested-PCR. They also had a liver biopsy
compatible with chronic hepatitis. The test was positive in 101 of the 106 (95%) sera from patients in the
study group and negative in 38 of the 39 (97%) sera from those in the control group, showing an
accuracy of 96%. According to these results, our EIA could be used to detect anti-HCV in the serum of
patients infected with hepatitis C virus.
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Chronic hepatitis C is a serious health problem
worldwide (Hoofnagle 1997). Approximately half
of the individuals with this infection became in-
fected via the parenteral route mainly through
blood transfusions or intravenous drug abuse (Al-
ter 1995).  After exposure, chronic liver disease
occurs in at least 85% of patients, and 20% of these
will eventually develop cirrhosis, with or without
hepatocellular carcinoma (Seeff 1997).
Hepatitis C virus (HCV) genome is a positive
sense RNA molecule, which encodes a polyprotein
of around 3,000 amino acids. This protein is
cleaved into the structural and non-structural pep-
tides, which are used in diagnostic tests for anti-
bodies against HCV (Bradley 1992). Soon after the
virus was cloned in 1989, a diagnostic test for anti-
HCV was developed, using a single fusion non-
structural protein from the 5-1-1 region in an en-
zyme immunoassay (EIA) format (Kuo et al. 1989).
However, this test had a limited sensitivity and a
high frequency of false-positive results (Medina
& Schiff 1995).
A second-generation test was subsequently
developed, including a structural protein (C22) in
addition to the non-structural component and this
led to an improvement in the sensitivity and speci-
ficity of the test (Medina & Schiff 1995, Gretch
1997). More recently, a third-generation EIA has
been produced including an antigen from a non-
structural region (NS5), but its true accuracy is still
under evaluation (Medina & Schiff 1995, Gretch
1997).
Although these newer tests, with structural and
non-structural antigens, have improved the diag-
nostic accuracy of HCV infection, little has been
described about an EIA using only a structural re-
combinant antigen.  The aim of the current study
was to evaluate an EIA for anti-HCV detection,
using a structural recombinant antigen (C22) in the
solid-phase as the target for anti-HCV detection.
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PATIENTS AND METHODS
Patients - Serum samples of 145 patients were
divided in two groups: a control group of 39 pa-
tients with non-C hepatitis (10 acute hepatitis A,
10 acute hepatitis B, 9 chronic hepatitis B, and 10
autoimmune hepatitis) and a study group consist-
ing of 106 patients with chronic HCV infection.
Eighty-one (76%) of the 106 patients were males
and their median age was 34 (range: 18-69) years.
Seventy-six (72%) patients were white. Fifty-six
(53%) patients had a history of parenteral exposi-
tion and 40 (38%) presented symptons. In the study
group all patients had anti-HCV detected by a com-
mercially available EIA (Abbott), and persistent
alanine aminotransferase (ALT) elevation (more
than six months) or a positive serum HCV-RNA.
Persistent ALT elevation was detected in 100
(94%) of the 106 patients and serum HCV-RNA
was detected in 95 (90%) patients.  In addition, an
inclusion criterion for the study group was that the
patients should have had a liver biopsy compat-
ible with chronic hepatitis. The histological prepa-
rations were submitted to semiquantitative analy-
sis (grading of necroinflammatory activity and
staging), as described by Desmet et al. (1994).
Methods - At the beginning of the study, se-
rum samples anti-HCV were tested with a com-
mercially available second-generation ELISA spe-
cific for HCV structural and nonstructural polypep-
tides, following the instructions of the suppliers
(Abbott Laboratories, North Chicago, IL).  Nested-
PCR, using primers targeted to the 5' untranslated
region, as previously described by Shindo et al.
(1991), detected HCV-RNA.
For patients in the control group, serum IgM
anti-HAV, HBsAg, IgM and total anti-HBc were
assayed using ELISA (Abbott Laboratories, North
Chicago, IL). Autoantibodies (ANA and SMA)
were tested using indirect immunofluorescence.
Anti-HCV EIA was designed to detect anti-
HCV core IgG using in the solid-phase only a re-
combinant C22 antigen produced by BioMérieux
(Lyon, France).  This antigen encodes the N-ter-
minal 48 amino acids of the HCV core protein. All
serum samples were stored at -20oC.  In brief, the
wells of microtiter plates (Hemobag) were coated
overnight at 4oC with 100 µl volume of C22 anti-
gen (5 µg/ml) in carbonate buffer (10 mM, pH 9.6).
Thereafter, the wells were washed with phosphate
buffer saline (PBS), containing 0.05% Tween-20
(PBS/T) and blocked over-night at 4oC with 100
µl of human albumin in PBS (1%). The plate was
washed three times with PBS/T, and 100 µl of se-
rum diluted (1/100) in PBS containing 1% albu-
min (pH 7.2) were added and incubated at 37o for
60 min. The plate was washed a further three times
with PBS/T, and 100 ml of horseradish peroxidase
goat anti-human IgG (Sigma), diluted as serum
samples (1/100), were added to each well. The plate
was incubated for 60 min at 37oC and washed three
more times with PBS/T. Then, 100 µl of o-phe-
nylenediamine (in citrate buffer) was added to each
well and incubated for 15 min at room tempera-
ture in the dark, with the reaction being stopped
by the addition of 100 µl of H2SO4 (1N). The color
was read in a micro-titer plate reader at a wave-
length of 492 nm.
Sera from three healthy subjects and from three
patients with chronic HCV hepatitis, which had
previously been tested for anti-HCV antibodies by
two commercial tests, were used as negative and
positive controls. Test samples with an optic den-
sity (OD) greater than twice the mean absorbance
of the three negative control sera were considered
reactive for anti-HCV C22 IgG. The mean titer of
anti-HCV IgG was considered the OD/cut-off ra-
tio.
The local ethical committee approved this
study. Results were compared using the Chi-square
test, T-test, Fisher’s exact test and  Spearman rank
correlation.  A two-tailed p value of less than 0.05
was considered statistically significant.
RESULTS
The assay was positive in 101 of 106 serum
from patients in the study group and negative in
38 of 39 serum from patients in control group
(Table I). Using the commercial assay as the gold-
standard test, the new test had a sensitivity of 95%
and a specificity of 97%, positive and negative
predictive values of 99% and 88%, respectively,
and an accuracy of 96%.
Furthermore, our EIA was positive in 93 of 95
(98%) patients who were HCV-RNA positive and
negative in 3 of 11 (27%) patients without vire-
mia. Interestingly, the mean titers of OD/cut-off
TABLE I
Results of the enzyme immunoassay (EIA) in 145
patients with hepatitis in relation to a commercial
assay (Abbott®)
      ELISA second-generation (Abbott®) Total
Positive Negative
positive 101 1 102
EIA
negative 5 38 43
Total 106 39 145
Sensitivity = 95%;  specificity = 97%; positive predictive
value = 99%; negative predictive value = 88%
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value for the EIA from serum samples of 95 pa-
tients positive for HCV-RNA (OD/cut-off = 3.47
± 1.12) were significantly higher (p = 0.001) than
HCV-RNA negative of 11 patients (OD/cut-off =
2.27 ± 1.29), (Figure). We did not find any corre-
lation (p = NS) between the mean titers of OD/cut-
off for the EIA and histological activity, using
Spearman rank correlation (Table II).
Katayama et al. (1992), using only one synthetic
peptide (p22) derived from the structural region of
HCV, found that the assay had more accuracy than
first-generation tests for the diagnosis of HCV in-
fection in the acute phase and for blood screening.
A possible explanation for these results is that a struc-
tural antibody would appear much earlier and more
persistently than antibodies against the non-struc-
tural region of HCV.  Manzini et al. (1993), using
one structural synthetic peptide for anti-HCV de-
tection, found a highly significant correlation be-
tween this test and two commercial available im-
munoassays of first and second-generation.
More recently, Trowbridge et al. (1996), evalu-
ating an assay using only one recombinant antigen
(C22) in the solid-phase, tested 453 serum samples
submitted for routine anti-HCV screening and com-
pared it with a third-generation EIA (Ortho®).
They found a significant correlation between these
two tests and only four samples showed discor-
dant results.  Using just one structural recombi-
nant antigen (C22), we also found a significant
correlation between our EIA and a commercial
second-generation assay (Abbott®). In addition,
we found a direct correlation between the mean
titers of OD/cut-off using EIA and viraemia, de-
tected by nested-PCR, although the number of
HCV-RNA negative samples was small.
Trowbridge et al. (1996) also described a sig-
nificant correlation between the anti-HCV core
titers and viraemia.  Furthermore, Chen et al.
(1995), using an anti-HCV core assay, also found
a correlation between the titers of anti-HCV core
IgG and the serum levels of HCV-RNA, detected
by a competitive PCR.  These results suggest that
patients with high titers of anti-HCV core are most
likely to be viraemic, but further studies with a
larger numbers of patients are necessary to con-
firm these findings. Thus, the use of the OD titers
by anti-HCV core test may be a helpful alterna-
tive to PCR, particularly in places where this test
is not widely available.
In this study, we did not find a correlation be-
tween the mean titers of OD/cut-off for the EIA
and histological activity, as was also not found by
Shindo et al. (1995). However, these same authors
found a direct correlation between the mean titers
of anti-HCV and HCV-RNA levels in liver tissue
(Shindo et al. 1995).
According to our results, this “in house” EIA is
comparable in terms of accuracy to a commercial
second-generation assay.  It is an easy test to per-
form and appears to be less expensive than com-
mercially available assays for the diagnosis of hepa-
titis C virus infection. In addition, it is important
that these findings could be confirmed more widely,
using the EIA for serum-epidemiological surveys.
TABLE II
Correlation between the mean titers of  optic density/
cut-off  for the enzyme immunoassay in  relation to
histological  grading  and  staging  (p = NS)
Histological  Numerical grading and staging system
features
0 1 2 3 4
Portal activity 1,7 3,6 3,3 3,5 3,4
Lobular activity 2,9 3,2 3,6 3,0 —
Staging 3,2 3,4 3,3 3,5 3,3
The mean  titers  of optic density/cut-off  for  the enzyme
immunoassay from serum  samples  of  106 patients,  95  posi-
tive  and  11  negative  for  RNA  of hepatitis C  virus  (HCV).
The difference  is statistically  significant (p = 0.001).
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DISCUSSION
Since 1989, the sequence analysis of the HCV-
genome has allowed the production of assays with
synthetic peptides and recombinant antigens for
anti-HCV detection.  Following the confirmation
of the limited accuracy of the first-generation tests,
which incorporated only non-structural antigens,
a series of immunoassays have been developed.
These new tests, incorporating one structural syn-
thetic peptide or more than two proteins, includ-
ing one from the structural region, had proven to
be more accurate (Medina & Schiff 1995, Gretch
1997).  However, few studies have been published
using only one structural recombinant antigen.
720 Enzyme Immunoassay for Anti-HCV Detection  EPA Lopes et al.
REFERENCES
Alter MJ 1995. Epidemiology of hepatitis C in the west.
Semin Liver Dis 15: 5-14.
Bradley DW 1992. Virology, molecular biology, and
serology of hepatitis C virus. Transf Med Rev 6: 93-
102.
Chen M, Sönnerborg A, Sällberg M 1995. Levels of
hepatitis C virus (HCV) RNA in serum and their
relationship to levels of immunoglobulin M and G
antibodies against HCV core protein. J Clin
Microbiol 33: 778-780.
Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer
P 1994. Classification of chronic hepatitis: diagno-
sis, grading and staging. Hepatology 19: 1513-1520.
Gretch DR 1997. Diagnosis tests for hepatitis C.
Hepatology 26 (Suppl.1): 43S-47S.
Hoofnagle JH 1997. Hepatitis C: the clinical spectrum
of disease. Hepatology 26 (Suppl. 1): 15S-20S.
Katayama T, Mazda T, Kikuchi S, Harada S, Matsuura
Y, Chiba J, Ohba H, Saito I, Miyamura T 1992.
Improved serodiagnosis of non-A, non-B hepatitis
by an assay detecting antibody to hepatitis C virus
core antigen. Hepatology 15: 391-394.
Kuo G, Choo Q-L, Alter HG, Gitnick GI, Redeker AG,
Purcell RH, Miyamura T, Dienstag JL, Alter MJ,
Stevens CE, Tegtmeier GE, Bonino F, Colombo M,
Lee WS, Kuo C, Berger K, Shuster JR, Overby LR,
Bradley DW, Houghton M 1989. An assay for cir-
culating antibodies to a major etiologic virus of hu-
man non-A, non-B hepatitis. Science 244: 362-364.
Manzini P, Calvo PL, Brunetto MR, Baldi M, Abate
ML, Oliveri F, Negro F, Balzola F, Saracco G,
Verme G, Chiba J, Miyamura T, Bonino F 1993.
Clinical significance of the antibody to the putative
core protein of hepatitis C virus in patients with
chronic liver disease. Liver 13: 222-226.
Medina M, Schiff ER 1995. Hepatitis C: diagnosis as-
says. Semin Liver Dis 15: 33-40.
Seeff LB 1997. Natural history of hepatitis C.
Hepatology 26 (Suppl. 1): 21S-28S.
Shindo M, Arai K, Sokawa Y, Okuno T 1995. The viro-
logical and histological states of anti-hepatitis C vi-
rus-positive subjects with normal liver biochemical
values. Hepatology 22: 418-425.
Shindo M, Di Bisceglie AM, Cheung L, Shih JWK,
Cristiano K, Feinstone SM, Hoofnagle JH 1991.
Decrease in hepatitis C viral RNA during alpha in-
terferon therapy for chronic hepatitis C. Ann Intern
Med 115: 700-704.
Trowbridge R, Sloots TP, Buda P, Faoagali J, Hyland
C, Young I. Gowans EJ 1996. An ELISA for the
detection of antibody to the core antigen of hepatitis
C virus: use in diagnosis and analysis of indetermi-
nate samples. J Hepatol 24: 532-538.
